Generex Biotechnology Corporatio (GNBT) 0.0126 $GNBT
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8vnnk/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Bayer AG - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Tobira Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/v8vnnk/deep_vein
BMY: 69.27 (+1.38), TBRA: 17.24 (+0.72)
Generex Announces Capital Investment
PR Newswire - Wed Jun 24, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it entered into a securities purchase agreement with an institutional investor on June 24, 2015. The investor has agreed to purchase in a private placement an aggregate of 500 shares of the Company's newly designated non-voting Series G 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $500,000. An aggregate of 66,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date upon which the Company's stockholders approve an increase in the Company's authorized capital, the investor may, in its sole determination, elect to purchase, in one or more purchases, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $500,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing.
Generex Biotechnology Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:18AM CDT
Product Pipeline Review - 2014
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 69.27 (+1.38), RGDO: 1.21 (unch)
Generex to partner with NHTherapeutics to utilise the RapidMist Buccal Delivery Technology for Leuprolide
M2 - Wed May 27, 3:44AM CDT
Drug delivery company Generex Biotechnology (OtherOTC:GNBT) disclosed on Tuesday the launch of a Memorandum of Understanding with NHTherapeutics,(NHT) to co-develop a formulation for the delivery of Leuprolide into the human body through the buccal mucosa using the proprietary RapidMist buccal drug delivery system.
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist(TM) Buccal Delivery Technology for Leuprolide
CNW Group - Tue May 26, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a Memorandum of Understanding with NHTherapeutics, Inc. (www.nhtherapeutics.com; NHT) pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMistTM buccal drug delivery system.
US Cancer Vaccine Market Outlook 2020
M2 - Tue May 26, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhhwzb/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2020" report to their offering. Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies. Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years. Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines in encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy. Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pyroli and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies. US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines. "US Cancer Vaccine Market Outlook 2020" Report Highlight: - US Cancer Vaccine Market Analysis - Cancer Vaccine with Orphan Status - US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase - US Cancer Vaccine Clinical Pipeline: 187 Vaccines - Clinical Insight of Marketed Cancer Vaccines in US - Marketed Cancer Vaccine in US: 5 Vaccines - FDA Regulations for Clinical Trials of Cancer Vaccines Clinical Insight of Marketed Cancer Vaccines in US - Bladder Cancer Vaccine - ID Biomedical (PACIS?) - Bladder Cancer Vaccine - Organon Teknika (OncoTICE) - Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil?) - Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix?) - Prostate Cancer - Dendreon Corporation (Provenge?) Companies Mentioned - Aduro BioTech - Advaxis - Antigen Express - Argos Therapeutics - Bavarian Nordic - Celldex Therapeutics - Cosmo Pharmaceuticals - Dendreon Corporation - GSK - Galena Biopharma - Generex Biotechnology - Gradalis - Merck - NewLink Genetics - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/bh...er_vaccine
ARGS: 6.45 (+0.69), ADRO: 30.58 (+0.28), MRK: 57.95 (+0.57), CLDX: 24.89 (+0.42), NLNK: 46.82 (+2.23), GALE: 1.63 (+0.10), GSK: 42.45 (+0.65)
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
PR Newswire - Thu May 14, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine under development at the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). The current analysis was performed on data that was examined one year after the last patient was enrolled into the trial. The ASCO meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Is Generex Now A Cannabis Play?
Nick Cox - at Seeking Alpha - Tue May 05, 3:52PM CDT
Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split
PR Newswire - Mon May 04, 8:30AM CDT
Dividend to occur after completion of reverse stock split, definitive licensing agreement, and effective registration of SMFI securities
Penny Stocks Buzz for Valmie Resources, Breathe Ecig, Elite Data Services, CANNAGROW, Revolutionary Concepts, and Generex Biotechnology
PR Newswire - Fri Apr 24, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), Breathe Ecig (OTCMKTS:BVAP), Elite Data Services (OTCBB
EAC), CANNAGROW (OTCMKTS:CGRW), Revolutionary Concepts (OTCMKTS:REVO), and Generex Biotechnology (OTCMKTS:GNBT).
Generex Announces New $11 Million Collaboration on Buccal Cannabis
CNW Group - Thu Apr 23, 8:45AM CDT
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding
Generex Announces Presentation of Data Correlating Immune Response with Reduction of Relapse in AE37 Phase II Breast Cancer Trial at AACR 2015
PR Newswire - Tue Apr 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA from April 18 to 22.
Generex Acknowledges the Contributions of Its Chairman
CNW Group - Tue Apr 07, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the resignation of John P. Barratt as a member of the Company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the Generex Board of Directors will take effect on April 30, 2015.
Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8vnnk/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Bayer AG - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Laboratorios Farmaceuticos Rovi, S.A. - Merrion Pharmaceuticals Plc - Tobira Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/v8vnnk/deep_vein
BMY: 69.27 (+1.38), TBRA: 17.24 (+0.72)
Generex Announces Capital Investment
PR Newswire - Wed Jun 24, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it entered into a securities purchase agreement with an institutional investor on June 24, 2015. The investor has agreed to purchase in a private placement an aggregate of 500 shares of the Company's newly designated non-voting Series G 9% Convertible Preferred Stock ("convertible preferred stock"
and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion of the convertible preferred stock ("warrants" at the closing. The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's common stock issuable upon conversion of such shares of convertible preferred stock. Each unit will be sold at a negotiated price of $1,000 for an aggregate purchase price of $500,000. An aggregate of 66,666,666 shares of the Company's common stock will be issuable upon conversion of, or exercise of, the convertible preferred stock and warrants issued at the closing. In addition, until the one year anniversary of the date upon which the Company's stockholders approve an increase in the Company's authorized capital, the investor may, in its sole determination, elect to purchase, in one or more purchases, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $500,000, which units will be identical to the units of convertible preferred stock and warrants issued in connection with the initial closing. Generex Biotechnology Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:18AM CDT
Product Pipeline Review - 2014
Venous (Vein) Thrombosis - Pipeline Review, H1 2015 Report Gives Vital Latest News and Deals
M2 - Mon Jun 08, 6:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjcg3h/venous_vein) has announced the addition of the "Venous (Vein) Thrombosis - Pipeline Review, H1 2015" report to their offering. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Venous (Vein) Thrombosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Venous (Vein) Thrombosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Venous (Vein) Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Astellas Pharma Inc. - Bayer AG - Bristol-Myers Squibb Company - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. For more information visit http://www.researchandmarkets.com/research/rj...enous_vein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMY: 69.27 (+1.38), RGDO: 1.21 (unch)
Generex to partner with NHTherapeutics to utilise the RapidMist Buccal Delivery Technology for Leuprolide
M2 - Wed May 27, 3:44AM CDT
Drug delivery company Generex Biotechnology (OtherOTC:GNBT) disclosed on Tuesday the launch of a Memorandum of Understanding with NHTherapeutics,(NHT) to co-develop a formulation for the delivery of Leuprolide into the human body through the buccal mucosa using the proprietary RapidMist buccal drug delivery system.
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist(TM) Buccal Delivery Technology for Leuprolide
CNW Group - Tue May 26, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced that it has entered into a Memorandum of Understanding with NHTherapeutics, Inc. (www.nhtherapeutics.com; NHT) pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMistTM buccal drug delivery system.
US Cancer Vaccine Market Outlook 2020
M2 - Tue May 26, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhhwzb/us_cancer_vaccine) has announced the addition of the "US Cancer Vaccine Market Outlook 2020" report to their offering. Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies. Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years. Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines in encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy. Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pyroli and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies. US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines. "US Cancer Vaccine Market Outlook 2020" Report Highlight: - US Cancer Vaccine Market Analysis - Cancer Vaccine with Orphan Status - US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase - US Cancer Vaccine Clinical Pipeline: 187 Vaccines - Clinical Insight of Marketed Cancer Vaccines in US - Marketed Cancer Vaccine in US: 5 Vaccines - FDA Regulations for Clinical Trials of Cancer Vaccines Clinical Insight of Marketed Cancer Vaccines in US - Bladder Cancer Vaccine - ID Biomedical (PACIS?) - Bladder Cancer Vaccine - Organon Teknika (OncoTICE) - Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil?) - Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix?) - Prostate Cancer - Dendreon Corporation (Provenge?) Companies Mentioned - Aduro BioTech - Advaxis - Antigen Express - Argos Therapeutics - Bavarian Nordic - Celldex Therapeutics - Cosmo Pharmaceuticals - Dendreon Corporation - GSK - Galena Biopharma - Generex Biotechnology - Gradalis - Merck - NewLink Genetics - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/bh...er_vaccine
ARGS: 6.45 (+0.69), ADRO: 30.58 (+0.28), MRK: 57.95 (+0.57), CLDX: 24.89 (+0.42), NLNK: 46.82 (+2.23), GALE: 1.63 (+0.10), GSK: 42.45 (+0.65)
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
PR Newswire - Thu May 14, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine under development at the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). The current analysis was performed on data that was examined one year after the last patient was enrolled into the trial. The ASCO meeting will be held from May 29 to June 2, 2015 in Chicago, IL.
Is Generex Now A Cannabis Play?
Nick Cox - at Seeking Alpha - Tue May 05, 3:52PM CDT
Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split
PR Newswire - Mon May 04, 8:30AM CDT
Dividend to occur after completion of reverse stock split, definitive licensing agreement, and effective registration of SMFI securities
Penny Stocks Buzz for Valmie Resources, Breathe Ecig, Elite Data Services, CANNAGROW, Revolutionary Concepts, and Generex Biotechnology
PR Newswire - Fri Apr 24, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Valmie Resources (OTCBB:VMRI), Breathe Ecig (OTCMKTS:BVAP), Elite Data Services (OTCBB
EAC), CANNAGROW (OTCMKTS:CGRW), Revolutionary Concepts (OTCMKTS:REVO), and Generex Biotechnology (OTCMKTS:GNBT). Generex Announces New $11 Million Collaboration on Buccal Cannabis
CNW Group - Thu Apr 23, 8:45AM CDT
Generex to receive $10M in common stock, a warrant, & $1M in R&D funding
Generex Announces Presentation of Data Correlating Immune Response with Reduction of Relapse in AE37 Phase II Breast Cancer Trial at AACR 2015
PR Newswire - Tue Apr 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) announced today presentation of data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine correlating local immune response to a reduction in relapse. AE37 is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex. The presentation was made at the American Association for Cancer Research (AACR) Annual Meeting held in Philadelphia, PA from April 18 to 22.
Generex Acknowledges the Contributions of Its Chairman
CNW Group - Tue Apr 07, 3:01PM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the resignation of John P. Barratt as a member of the Company's Board of Directors. For medical reasons, Mr. Barratt has made the decision to take full retirement from his myriad corporate responsibilities. The resignation from the Generex Board of Directors will take effect on April 30, 2015.
